In response to: “Reply to research letter” - 09/11/20
Funding sources: Supported in part by a grant (P30-AR-069589-03) from the National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases to Dr Gelfand. |
|
Conflicts of interest: Dr Wan is supported in part by a grant from Pfizer. Dr Winthrop receives grants from Bristol-Myers Squibb and Pfizer and is a consultant for UCB, AbbVie, Lilly, Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, and Roche. Dr Gelfand served as a consultant for Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Janssen Biologics, Novartis Corp, Regeneron, UCB (Data Safety and Monitoring Board), Sanofi, and Pfizer Inc, receiving honoraria; receives research grants (to the Trustees of the University of Pennsylvania) from AbbVie, Janssen, Novartis Corp, Sanofi, Celgene, Ortho Dermatologics, and Pfizer Inc; and has received payment for CME work related to psoriasis that was supported indirectly by Eli Lilly and Company and Ortho Dermatologics. Dr Gelfand is a copatent holder of resiquimod for treatment of cutaneous T-cell lymphoma and is a deputy editor for the Journal of Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology. Dr Shin has no conflicts of interest to declare. |
|
IRB approval status: Not applicable. |
|
Reprints not available from the authors. |
Vol 83 - N° 6
P. e445 - décembre 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?